Merrimack Pharmaceuticals Inc. (MACK)

10.90
0.08 0.74
NASDAQ : Health Technology
Prev Close 10.82
Open 10.72
Day Low/High 10.72 / 11.19
52 Wk Low/High 9.68 / 39.90
Volume 166.61K
Avg Volume 153.20K
Exchange NASDAQ
Shares Outstanding 13.34M
Market Cap 134.06M
EPS -12.10
Div & Yield N.A. (N.A)

Latest News

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

NewLink Jumps on Orphan Drug Status for Melanoma Treatment -- Biotech Movers

The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.

Merrimack Announces Settlement Of Convertible Note Litigation

Merrimack Announces Settlement Of Convertible Note Litigation

- Agreement Resolves Outstanding Litigation Associated with Merrimack's Asset Sale to Ipsen -

Verastem Shares Are Exploding 50% -- Here's Why

Verastem Shares Are Exploding 50% -- Here's Why

The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers

Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.

Merrimack Announces Date Of One-for-Ten Reverse Stock Split

Merrimack Announces Date Of One-for-Ten Reverse Stock Split

- Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on September 6, 2017 -

Merrimack Appoints Thomas Needham As Chief Business Officer

Merrimack Appoints Thomas Needham As Chief Business Officer

Industry veteran to help shape and execute value creation strategy across Merrimack's broad development pipeline

Merrimack Announces Expansion Of Senior Management Team With Appointment Of Sergio Santillana As Chief Medical Officer And Ellen Forest As Head Of Human Resources

Key Appointments to Help Drive Merrimack's Refocused Research and Clinical Development Strategy

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration

Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Merrimack Announces Management Change

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

First Week Of MACK May 19th Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the May 19th expiration.

These 5 Stocks Under $10 Could Explode Up Soon

These 5 Stocks Under $10 Could Explode Up Soon

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

First Week of MACK April 21st Options Trading

Investors in Merrimack Pharmaceuticals Inc. saw new options become available this week, for the April 21st expiration.

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

Immunomedics, Seattle Genetics Lead Biotech Movers on Deal News

The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

McKesson, Bristol-Myers and Varian were having a busy morning.

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

First Week of September 15th Options Trading For Merrimack Pharmaceuticals (MACK)

Investors in Merrimack Pharmaceuticals Inc. saw new options begin trading this week, for the September 15th expiration.

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

Closing Bell: Alibaba's Ma Meets With Trump; Nasdaq Hits Record

The Dow Jones Industrial Average's road to 20,000 has another detour as a selloff in crude spooks the energy sector.

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference

The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.